Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Matilde Lleonart Pajarin LinkedIn Twitter Orcid Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Projects Relevancia terapéutica de las Células Madre de Cáncer en carcinoma epidermoide Faringo-Laríngeo IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea Funding agency: Fundació Institut de Recerca HUVH Funding: 46800 Reference: PRED-VHIR-2014-12 Duration: 01/06/2015 - 31/05/2018 Identificación de nuevos factores pronóstico y diagnóstico en cáncer basados en microRNAs y sus proteínas diana que se asocian a tumores de carácter más agresivo IP: Matilde Lleonart Pajarin Collaborators: César Serrano Garcia, Angel García Jiménez, Teresa Moline Marimon, Carmela Iglesias i Felip, Vicente Peg Camara Funding agency: Instituto de Salud Carlos III Funding: 145200 Reference: PI12/01104 Duration: 01/01/2013 - 30/06/2017 Desarrollo de dianas terapéuticas basadas en microRNAs sobreexpresados en cáncer de pulmón IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Fundación BBVA Funding: 147000 Reference: BBVA/CONV.LLEONART/2010 Duration: 01/06/2010 - 01/06/2014 Genetic screen for detecting genes expressed in embryonic stem cells that bypass immortalisation in primary cells IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 31959 Reference: MERG-510300 Duration: 01/02/2004 - 31/01/2005 Pagination First page « Previous page ‹ … Page 4 Page 5 Current page 6 Page 7 Page 8 … Next page › Last page »
